Nurisyah Sitti, Iyori Mitsuhiro, Hasyim Ammar Abdurrahman, Sakamoto Akihiko, Hashimoto Hinata, Yamagata Kyouhei, Yamauchi Saya, Amru Khaeriah, Zainal Kartika Hardianti, Idris Irfan, Yoshida Shigeto, Djaharuddin Irawaty, Syafruddin Din, Bukhari Agussalim, Asih Puji Budi Setia, Yusuf Yenni
Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.
Dr. Tadjuddin Chalid Hospital, Makassar 90241, Indonesia.
Antibodies (Basel). 2023 Sep 21;12(3):60. doi: 10.3390/antib12030060.
To fight the COVID-19 pandemic, immunity against SARS-CoV-2 should be achieved not only through natural infection but also by vaccination. The effect of COVID-19 vaccination on previously infected persons is debatable.
A prospective cohort was undergone to collect sera from unvaccinated survivors and vaccinated persons-with and without COVID-19 pre-infection. The sera were analyzed for the anti-receptor binding domain (RBD) titers by ELISA and for the capacity to neutralize the pseudovirus of the Wuhan-Hu-1 strain by luciferase assays.
Neither the antibody titers nor the neutralization capacity was significantly different between the three groups. However, the correlation between the antibody titers and the percentage of viral neutralization derived from sera of unvaccinated survivors was higher than that from vaccinated persons with pre-infection and vaccinated naïve individuals (Spearman correlation coefficient () = -0.8558; 95% CI, -0.9259 to -0.7288), < 0.0001 vs. -0.7855; 95% CI, -0.8877 to -0.6096, < 0.0001 and -0.581; 95% CI, -0.7679 to -0.3028, = 0.0002, respectively), indicating the capacity to neutralize the virus is most superior by infection alone.
Vaccines induce anti-RBD titers as high as the natural infection with lower neutralization capacity, and it does not boost immunity in pre-infected persons.
为抗击新冠疫情,不仅应通过自然感染,还应通过接种疫苗来实现对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的免疫。新冠疫苗接种对既往感染者的效果存在争议。
进行一项前瞻性队列研究,收集未接种疫苗的康复者以及接种疫苗者(无论之前是否感染过新冠)的血清。通过酶联免疫吸附测定(ELISA)分析血清中的抗受体结合域(RBD)滴度,并通过荧光素酶测定评估其中和武汉-1株假病毒的能力。
三组之间的抗体滴度和中和能力均无显著差异。然而,未接种疫苗的康复者血清中抗体滴度与病毒中和百分比之间的相关性高于既往感染过新冠的接种者和未感染过新冠的接种者(斯皮尔曼相关系数()=-0.8558;95%置信区间,-0.9259至-0.7288),分别与-0.7855;95%置信区间,-0.8877至-0.6096,<0.0001和-0.581;95%置信区间,-0.7679至-0.3028,=0.0002相比),表明仅通过感染中和病毒的能力最为优越。
疫苗诱导的抗RBD滴度与自然感染一样高,但中和能力较低,并且对既往感染者不会增强免疫力。